The Global Antibiotic Resistance Market is estimated to reach over USD 18.34 billion by 2030, exhibiting a CAGR of 6.1% during the forecast period.
Antibiotics are antimicrobial chemicals that are used to treat bacterial infections. Strokes, sinus infections, urinary tract infections, ear infections, pneumonia, skin infections, and other diseases are all treated with them. The market has been supported by the high prevalence of antibiotic-resistance illnesses, and the rise of multi-drug resistant bacteria are expected to boost the market expansion in the next coming years. In addition, the accelerated need for novel therapies will further provide potential opportunities for the growth of the antibiotic resistance market over the upcoming years. The discovery of advanced prospect molecules and the introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to propel the market growth during the forecast period.
However, lack of investor concern in the research and development of resistance therapies, shortage of educated employees and strict safety rules are factors that may limit the growth of the target market during the forecast period. Advances in nutrition, medicine, and vaccination are factors that are likely to generate profitable revenue growth possibilities for participants in the worldwide Antibiotic Resistance market throughout the forecast period.
Market Segmentation:
The Antibiotic Resistance market is segmented based on pathogen type and applications. Based on pathogen type, the market is segmented as DRSP, DRC, CD, MRSA, DRNG, DRNTS, and Other Pathogen. Based on Technology market is segmented into antibiotics, Phage, Pep/Lys, Antibodies, Vaccine and others.
Based on pathogen type, the CD segment is accounted as a significant contributor to the Antibiotic Resistance market.
The CD category is expected to hold a major share in the global Antibiotic Resistance market in 2021. This is attributed to a number of cases in comparison to Gram-positive pathogens. They impose a high-cost burden as physicians are increasingly shifting towards novel antibiotics such as Allergan's Ayaz and Melinte Therapeutics' Vaporer. Also, these infections pose treatment challenges for physicians due to high resistance to current treatment alternatives.
Vaccine segment witnessed growth at a rapid rate
The vaccine segment is projected to grow at a rapid rate in the global antibiotic resistance market owing to the increasing prevalence of viral infectious diseases are one of the major threats affecting a large population across the globe. The incidence of coronavirus infection has affected millions of individuals worldwide, which has created a significant demand for vaccines. There is an increase in demand for vaccines, especially in countries such as the US, Germany, the UK, China, and India. Also, Leading operating actors were involved in research and development for the creation of extremely effective preventative vaccines, which resulted in the introduction of several new medicines to the market.
In the region, the North America Antibiotic Resistance market holds a significant revenue share.
The North America Antibiotic Resistance market is expected to register the highest market share in terms of revenue soon. The regional market's expansion is being aided by several new medicine launches and significant treatment costs. North America and Europe are growing their use of the antibiotic resistance sector as a result of greater individual awareness regarding antibiotic resistance in this region. Antibiotic-resistant infections are on the rise, and healthcare-acquired conditions are on the increase in the United States.
In addition, Europe is projected to grow at a rapid rate in the global Antibiotic Resistance market. Greater engagement in terms of investment to combat resistance and implementing proper usage and stewardship standards for the use of antibiotics will boost market expansion over the upcoming years. The increased acceptance of antibiotic resistance and the increasing incidence of infectious diseases are some of the prior causes projected to drive the evolution of the antibiotic resistance marker.
Competitive Landscape
The key players in the Antibiotic Resistance market have shifted their focus to bio-based components for product manufacturing and are implementing effective strategies such as mergers, acquisitions, and joint ventures of major and domestic players to strengthen their product portfolio and global market footprint. Some of the major key players in the Antibiotic Resistance market are "The Medicines Company, Melinta Therapeutics, Arsanis, Phage Technologies S.A, Westway Health, Alaxia SAS, Antabio S.A.S, Auspherix Ltd, BioFilm Pharma, Centauri Therapeutics Ltd, Combioxin SA, Da Volterra, Debiopharm International SA, Deinove, Neem Biotech Ltd, Northern,, Antibiotics Oy (Ltd), Nosopharm, NovaBiotics Ltd, Phico Therapeutics Ltd, Polyphor Ltd, QureTech Bio AB,SetLance Srl, Ultupharma AB, Vaxdyn, Vibiosphen, Bioaster, Vivexia, KBP Biosciences, Absynth Biologics, Spero Therapeutics, Merck, Symphogen, Warp Drive Bio, Johnson & Johnson (Janssen), Pfizer, Allergan, Novartis, AstraZeneca, Cipla, DSM Sinochem Pharmaceuticals, Wockhardt Ltd., VenatoRx Pharmaceuticals, MicuRx, Entasis Therapeutics, Merlion Pharmaceuticals, Aridis Pharmaceuticals Inc, Other Prominent Players"
By Technology 
